The molecular mechanisms leading to Cushing's disease are unclear. Inhibitors of cyclin-cyclin dependent kinase (CDK) complexes are regulators of the cell cycle and may function as tumour suppressor genes, many of which have been involved in the pathogenesis of several human malignancies. A member of this family, the p27/kip1 gene, maps to chromosome 12p13 and encodes an inhibitor of several cyclin-CDK complexes; these control the progression of the cell cycle from G1 to S-phase. Complete lack of p27/kip1 function, as occurs in the p27/kip1`knockout' mouse, produces a complex phenotype associated with the development of pituitary tumours, speci®cally those of the intermediate lobe corticotrophs. We therefore investigated whether structural and functional abnormalities of the p27/kip1 gene and loss at the chromosome 12p13 region were present in human corticotrophin (ACTH)-secreting pituitary tumours. We studied 21 pituitary tumours, of which 20 were ACTH-secreting (two of these had biochemical and histological features of`intermediate-lobe' tumours and one was malignant) while the remaining tumour was a prolactinoma; three ectopic secretors of ACTH (two bronchial and one thymic carcinoid); and a non-secretory thymic carcinoid. The whole coding region of the p27/ kip1 gene was screened for mutations by PCR ± SSCP analysis and/or direct sequencing, while tumour mRNA expression was analysed by means of a semi-quantitative duplex PCR. Three polymorphic microsatellite markers of the 12p13 region were used to assess loss of heterozygosity (LOH) in 12 samples. Finally, tumour p27/kip1 protein expression was assessed by immunohistochemistry using a monoclonal antibody in 12 samples suitable for analysis. No sequence abnormalities were found in any of the samples other than a previouslydescribed polymorphism. No LOH was observed in the tumours analysed. p27/kip1 mRNA expression was similar in tumour samples in comparison with normal pituitaries. Seven of the eight corticotroph tumours analysed by immunohistochemistry stained positive for p27/kip1, including the intermediate lobe. The only malignant pituitary tumour in the original series showed an absence of staining for p27/kip1. In addition, the three carcinoid tumours studied were negative on immunohistochemistry. Of a further three malignant pituitary tumours assessed, two (including a prolactinoma) were essentially negative, while the third was moderately positive. We conclude that mutations of the
Introduction
The molecular pathogenesis of pituitary tumours is as yet unclear. Attempts to identify genes related to speci®c pituitary growth have so far been disappointing, as non-speci®c oncogenes and tumour suppressor genes, as well as genes related to pituitary physiological regulation, have been found to be structurally normal in the majority of such tumours (Herman et al., 1993; Levy et al., 1994; Dahia et al., 1996) .
It has recently been reported that mice with a genomic`knockout' of the p27/kip1 gene develop multi-organ hyperplasia resulting in increased animal size and pituitary tumours that originate from intermediate lobe corticotrophs, but no other neoplasms (Fero et al., 1996; Nakayama et al., 1996; Kyiokawa et al., 1996) . Such tumours immunostain for corticotrophin (ACTH). The p27/kip1 gene maps to chromosome 12p13 and encodes for a 27 kd protein that is a member of the cyclin-kinase inhibitor proteins (CKIs) family, including cyclin-cyclin dependent kinase (CDK) complexes with CDK 2,3,4, and 6 (Poliak et al., 1994a; Poliak et al., 1994b; Toyoshima et al., 1994) . Some of these complexes, formed between D-type cyclins and CDK4/CDK6, mediate the phosphorylation of the retinoblastoma (Rb) protein and, through its inactivation, allow the progression of cell cycle from mid-G1. Another target for p27 regulation is the cyclin E/CDK2 complex, required for entry into S-phase from late G1 (Kato et al., 1994) . The p27 product is involved in pathways that sense both mitogenic and antiproliferative extrinsic signals: its activity is high in quiescent cells and declines during cell cycle progression (Polyak et al., 1994a) . There is evidence suggesting that p27 mediates G1 arrest induced by transforming growth factor-b, contact inhibition, or serum depriva-tion in epithelial cells (Polyak et al., 1994b; Qian et al., 1996) . Over-expressed p27 proteins cause cell cycle arrest (Polyak et al., 1994a; Hengst et al., 1996) . Also, p27 has been shown to promote cell dierentiation, as demonstrated by the induction of cell-surface speci®c markers indicative of dierentiation when ectopically expressed on myelomonocytic cells (Liu et al., 1996) .
Recent observation suggests that post-translational ubiquitin-mediated proteasomal proteolysis is a major regulator of p27 levels (Hengst et al., 1996; Pagano et al., 1995) . In addition, more recent evidence indicates that low p27 expression may correlate with poor survival in patients with certain malignancies (Fredersdorf et al., 1997; Catzavelos et al., 1997; Porter et al., 1997; Loda et al., 1997) . We therefore sought to verify whether p27 gene and/or its protein product might be involved in the pathogenesis of human pituitary tumours, speci®cally those with an ACTHsecreting phenotype.
Results
Four pituitary tumours of the 23 examined showed an aberrant migration pattern under all three SSCP conditions (Table 1 and Figure 1 ). The sequence of these samples revealed a heterozygous single base change at nucleotide 326 (codon 109), resulting in the replacement of valine by glycine (GTC ± GGC) in one of the alleles, a previously identi®ed polymorphism (Figure 1) . No other abnormalities were found in any of the tumours. The three normal pituitaries had valine at codon 109. The sequence of the two intermediate lobe tumours did not reveal mutations of the coding region of the p27 gene, and both samples contained valine at codon 109.
The expression of p27 relative to that of GAPDH, as expressed by RT ± PCR in 14 of the corticotroph tumours and the prolactinoma was compared to four normal pituitaries. The mean p27/GAPDH ratio was 1.67+0.71 (mean+s.d.), which was not signi®cantly dierent to the expression in the normal pituitary (1.46+0.67; P40.05, Student's t-test). Normal expression was seen in the tumour from patient 12, a nonsecretory carcinoid which was negative on p27/kip1 immunostaining. A representative gel is shown in Figure 2 . Twelve tumours tested for the D12S269 marker were informative, while ®ve and ten tumours were informative for the D12S363 and D12S364 markers, respectively. None of the tumours showed evidence of LOH in any of the three polymorphic markers (data not shown).
The immunohistochemical analysis revealed strong p27/kip1 staining in the two normal pituitaries (data not shown) and in six Cushing's adenomas, and also in the normal pituitary of one of the ectopic ACTH secretors (Table 1 ; Figure 3b 
Discussion
We failed to identify mutations of the entire coding region of the p27 in a series of pituitary tumours. The polymorphism of codon 109 observed in four of our samples, which has been previously identi®ed Morosetti et al., 1995) does not seem to confer any particular predisposition regarding cell growth or tumour development. To de®nitely exclude linkage to this gene by abnormalities of regions outside the range of our study (e.g. the promoter region) or identify deletions in the area encompassing the p27/kip1 gene, we searched for LOH of the 12p13 region by using polymorphic microsatellite markers in 12 pituitary tumours for which germline DNA was available. None of the tumours showed LOH of any of the three markers used. Although unlikely, it is possible that a homozygous deletion would have escaped detection if normal tissue was admixed in the sample. However, we minimised this possibility by obtaining tissue from the tumour core only and limiting the number of PCR cycles. Furthermore, our expression study showed normal levels of mRNA for p27/kip1 in all tumours assessed, including one which was subsequently noted to be negative on p27/kip1 protein immunostaining. These data suggest that changes in p27/kip1 gene structure or expression are not commonly implicated in the pathogenesis of human pituitary tumours, despite the striking phenotype observed in`knockout' mice for the p27/kip1 gene.
Our ®ndings are similar to those reported for the Rb gene in human pituitary tumours: the`knockout' animal model for the Rb gene also features a high incidence of pituitary tumours (Jacks et al., 1992) , but subsequent studies in humans failed to identify abnormalities of the Rb gene in such tumours (Cryns et al., 1993; Woloschak et al., 1996) . Because the function of p27/kip1 and Rb protein are interlinked, a possible explanation for the lack of abnormalities of the Rb gene in pituitary tumours could be a disruption of another factor related to Rb function, and p27/kip1 emerged as a potential candidate for this role. Since the product of the p27/kip1 gene is widely expressed, it was surprising that the only tumour type observed in thè knockout' animals arose from the pituitary. While an intermediate lobe does not exist distinctly in the adult human pituitary, most intermediate lobe cells are corticotrophs and secrete peptides derived from proopiomelanocortin (POMC), including ACTH and its cleavage products. We therefore speci®cally investigated whether ACTH-secreting pituitary tumours showed mutations of the p27 coding region or systematically demonstrated changes in mRNA expression; we also looked at two human tumours which showed certain intermediate lobe characteristics, as well as two carcinoids ectopically secreting ACTH and two non-ACTH secreting pituitary tumours.
Recent evidence has shown that p27/kip1 is mutated on very rare occasions in several human malignancies (Spirin et al., 1996; Kawamata et al., 1995; Morosetti et al., 1995; Ponce-Castaneda et al., 1995; Pietenpol et al., 1995) , unlike other cycle-cell regulators such as p16 and p53. Although p27/kip1 may function as a tumour suppressor gene, the absence of molecular abnormalities in various human tumours examined so far suggests that it is not a frequent target of cancer-type mutations in humans or, alternatively, that structural abnormalities are not the mechanism of inactivation of p27/kip1 in human tissues. As expected for an inhibitor of cell-cycle progression, p27/kip1 levels correlate inversely with the degree of proliferation in normal human tissues (Fredersdorf et al., 1997) . However, it has been reported that highly proliferative neoplasms or cell lines may express p27/kip1 (Fredersdorf et al., 1997; Catzavedos et al., 1997; Porter et al., 1997) , suggesting a more complex mechanism of p27/kip1 regulation. It has been postulated that the balance between the levels of p27 and their opposing factors, the cyclins, is an important element determining the degree of cell proliferation (Fredersdorf et al., 1997; Elledge et al., 1996) . Cell-cycle progression might occur when cyclin-CDK complexes rise above the inhibitory threshold set by cell-cycle inhibitors such as p27/kip1 (Ravitz et al., 1996) . p27/kip1 levels are maximal in G1-enriched fractions and decline as cyclin E accumulates: this implies that p27/kip1 continues to be synthesised in proliferating cells, which suggests that its expression may be regulated periodically. One proposed mechanism by which stimulated cells downregulate p27/kip1 levels is its sequestration from cyclin E-CDK2 by cyclin D-CDK 4 complexes (Ravitz et al., 1996) . This shift would free the cyclin E-CDK2 complex from p27/kip1 inhibition, and thereby allow cell progression through the S-phase. We also failed to detect signi®cant variations at the transcription level of the p27/kip1 message in pituitary tumours as compared with normal pituitaries. This is in agreement with recent reports describing a lack of correlation between the expression of p27/kip1 at mRNA and protein levels (Fredesdorf et al., 1997; Pagano et al., 1995) . Instead, post-translation ubiquitinmediated proteasomal proteolysis has been suggested as another major regulator of p27/kip1 levels (Pagano et al., 1995; Loda et al., 1997) . Hence the assessment of the p27/kip1 protein expression should provide evidence for an abnormal degradation of the protein if this were the mechanism of inactivation of p27 in those tumours. Ubiquitin-mediated proteolysis has been shown to be important for initiation of DNA synthesis in S. cerevisiae, where the cyclin kinase inhibitor p40 must be degraded in order to activate kinases responsible for entry into S-phase (Schwob et al., 1994) . The p27 product seems to play an analogous role to p40 in the mammalian cell cycle, suggesting a similar involvement of ubiquitination in regulating p27/kip1 activity. In fact, in normal human ®broblasts and the human osteosarcoma cell line MG63, ubiquitin-conjugating enzymes Ubc2 and Ubc3 exhibit less p27/kip1-ubiquitinating activity in quiescent than proliferating cells, which might account for the longer p27/kip1 half-life in quiescent cells (Pagano et al., 1995) . It appears that dierent cells regulate the p27/kip1 levels by dierent mechanisms, with either ubiquitination or sequestration by cyclin-CDK complexes predominating according to the responsivity of cells to speci®c signal transduction mechanisms, as seen by the dierential eects of TGF-b and EGF in ®broblasts (Ravitz et al., 1996) . Recent studies on the levels of p27/kip1 expression in breast and colon cancer have suggested that there is an inverse correlation between the tumour grade and the level of p27/kip1 expression (Fredersdorf et al., 1997; Catzavelos et al., 1997; Porter et al., 1997) . This may indicate a role for p27/kip1 protein as a prognostic factor in such tumours. The ®nding of p27/kip1 staining in the majority of pituitary adenomas in our series is compatible with a low degree of cell proliferation. It suggests that abnormal staining of p27/ kip1 is not a feature of benign corticotrophinomas, including the rare intermediate lobe tumours. However, the one malignant case of our original series stained negative for p27/kip1. Subsequent examination of three further pituitary tumours with intra-cranial metastases, two corticotrophinomas and one prolactinoma, revealed negative immunostaining in two. One of these, patient 27, has been previously reported as showing loss of heterozygosity at multiple genetic sites at ®rst surgical removal (Bates et al., 1995) , suggesting that it was likely to have been malignant ab initio. The third tumour was clearly p27/kip1 positive, although it too had appeared to be highly invasive at the time that this pathological specimen was removed, and was also ultimately lethal. This may suggest a role of p27/kip1 in some at least of the more aggressive corticotrophinsecreting (and possibly other) pituitary tumours, similar to that seen in the more aggressive subtypes of colon and breast cancers, which also do not express p27/kip1 protein on immunohistochemistry. We also found that the ectopic ACTH-secreting tumours stained negative for p27/kip1. The lack of staining in such tumours, which usually have low proliferation rates, may be due to tissue-speci®c expression of p27kip1 (Fredersdorf et al., 1997) . A recent report describing p27/kip1 protein expression in several endocrine tumours revealed decreased levels of p27/ kip1 in benign and malignant tumours in comparison with normal tissues (Lloyd et al., 1997 ). An unspeci®ed number of pituitary adenomas were shown to present 2 ± 8-fold lower p27/kip1 levels as compared to normal pituitaries. As the cell of origin of the pituitary adenomas analysed was not clearly stated, and no malignant pituitary tumour seems to have been included in that series, a direct comparison with the present study is not possible. However, the ®nding of an inverse correlation between p27/kip1 and Ki-67, an index of cell proliferation, in other endocrine tumours suggests that indeed low or absent p27/kip1 expression may indicate a more aggressive neoplastic behaviour.
In conclusion, we have shown that abnormalities of the p27/kip1 at the gene structure, mRNA or protein levels do not seem to be important in the pathogenesis of benign corticotroph tumour formation, and that the 12p13 region is not frequently deleted in such tumours. However, the lack of p27/kip1 staining in a malignant corticotrophinoma, as well as in two out of three further malignant pituitary tumours, suggests that p27/ kip1 inactivation may be related to more aggressive subforms of pituitary tumours.
Materials and methods

Tumour specimens
We examined 25 samples: 21 pituitary tumour samples (Table 1) , of which 20 were ACTH-secreting (two tumours had histological features compatible with an intermediate lobe origin and one tumour was a malignant corticotrophinoma) and one was a prolactinoma. One of the intermediate lobe tumours has previously been described in detail (Hale et al., 1988) , while the second was similar in histological, biochemical and associated clinical characteristics. The malignant corticotroph tumour was diagnosed based on the histological ®nding of tumour invasion of adjacent bone and distant bone metastases. Additionally, three ectopic secretors of ACTH were studied, two of which were bronchial carcinoids while the third one originated from the thymus, and also a non-secretory thymic carcinoid from a patient with multiple endocrine neoplasia type 1. For the expression studies we examined an additional four pituitaries from autopsies of patients dying of non-endocrine disease, for the immunocytochemical staining we also examined two pituitaries from patients dying from non-endocrine disease and the normal pituitary from one of the patients with a bronchial carcinoid.
The tumour tissue was obtained at the time of the surgery and stored at 7708C until assay. The two intermediate lobe tumours were available only as archival paran-embedded tissue. Paired constitutive tissue obtained from peripheral lymphocytes was available from 12 patients. Paranembedded tissue was available for analysis in all cases, but only that from 12 patients was suitable for immunohistochemical assay.
Finally, in view of our results, a further three malignant pituitary tumours were studied for p27/kip1 immunostaining. Patient 26 had a highly invasive prolactinoma which metastasised throughout the skull and was resistant to all modes of therapy: the tumour tissue was removed at autopsy. Patient 27 was 37 years old at the time that his highly invasive corticotrophinoma was surgically explored for the fourth time, following external beam radiotherapy 5 years previously; he died 3 years after this operation with intracerebral metastases. Patient 28 was 45 years old when his recurrent invasive corticotrophinoma was removed at craniotomy; this was followed by external beam radiotherapy, but he succumbed 4 years later with meningeal, spinal cord and cerebellar metastases.
Methods
RNA and DNA were extracted using the Tri-Reagent (Sigma, Poole, UK), according to the manufacturers' guidelines. Messenger RNA was transcribed into cDNA using random hexamers, as previously published (Dahia et al., 1996) .
Mutation analysis
Two-hundred nanograms of cDNA were used for PCR of the two coding exons of p27/kip1 in a 25-ml reaction containing 1.25 mM MgCl 2 , 0.4 mM of each primer (F1 s ATGTCAAACGTGCGAGTGTC and as TCTGT-AGTAGAACTCGGGCAA; F2 s TTGCCCGAFTTC-TACTACAGA and as TTACGTTTGACGTCTTCTGAG, manufactured by Genosys, Cambridge, UK), 200 mM dNTPs, 10 mM Tris-HCl, 50 mM KCl, and 0.125 U Taq DNA polymerase. Thirty cycles at 948C, 1 min; 588C, 1 min and 728C, 1 min were performed, with a starting denaturing cycle at 958C, 5 min; and a ®nal extension cycle at 728C for 10 min. DNA from the paran-embedded tissues was extracted using`GeneReleaser' (Cambio, Cambridge, UK), with modi®cations of the original protocol (SL Chew and MA Satta, personal communication). Brie¯y, a 5 m-thick fragment of paran-embedded tissue was mixed with 20 ml of`GeneReleaser' solution, heated at 978C for 10 min, followed by 5 min at 808C, and then subjected to a 50-ml PCR using 0.8 mM of each primers and remaining reagents as above. The PCR conditions were the same as described above, but the number of cycles was increased to 40. Because the size of fragment 2 (see primers above) was too large for the paran-embedded samples to be ampli®ed, internal primers were designed, originating fragments 2A (sense F2 primer as above, and as AGCGACCTGCAACC-GACG) and 2B (TGCGCTTAGATTCTTCTACT and antisense F2 primer, as above). The PCR products were labelled with a 32 P-dCTP (SA=6000 Ci/mmol, ICN Biochemicals, Thame, UK) as described (Dahia et al., 1996) , and subjected to single-strand conformation polymorphism (SSCP) analysis under three dierent conditions: on 0.56 MDE gels (AT Biochem, Philadelphia, PA) or 6% polyacrylamide gel containing 10% glycerol, both run overnight at 4 W, or on a 6% polyacrylamide gel without glycerol, run at 40 W for 2 h. Prior to running on a gel, the labelled products were digested with restriction enzymes FokI and HinfI (New England Biolabs, Taumus, Germany), according to the manufacturers' guidelines, to increase the sensitivity of the SSCP analysis by reducing fragment size. Three normal pituitaries obtained at autopsy from individuals who died of non-endocrine disorders were used as normal controls.
Samples that showed abnormal migration on the SSCP were sequenced with the Sequenase 2.0 PCR Direct Sequencing Kit (USB, Anachem, UK), using the method described by the manufacturer. The two intermediate lobe tumours were directly sequenced.
Semi-quantitative RT ± PCR
Four micromoles of p27F2 and 0.2 mM of glyceraldehyde phosphate dehydrogenase (GAPDH) primers (Dahia et al., 1996) were used in a semi-quantitative, duplex PCR with 200 ng tumour cDNA to assess the relative expression of the p27/kip1 gene. All other reagents and ampli®cation protocol were as above and a smaller number of cycles (n=26) were used to obtain products on the exponential phase of the synthesis curve. The intensity of the p27 product was compared with that of the GAPDH band using densitometry. The absorbance values for each band were measured using an imaging densitometer (Model GS-670, Biorad, Herts, UK) and the Molecular Analist/PC software (Biorad Image Analysis System). A ratio between the intensities of the two bands was obtained for each sample. Fifteen of the tumours were analysed in which sucient RNA was available, and compared to pituitary tissue from four autopsy patients dying from nonendocrine disease.
Loss of Heterozygosity (LOH) in the 12p13 region LOH analysis was carried out using polymorphic microsatellite markers located at the 12p13 region: D12S269, D12S363 and D12S364, and PCR performed as published (Morossetti et al., 1995) . In 12 cases, constitutive DNA was available for the LOH analysis. Radio-labelled PCR products were run on a 6% denaturing gel at 50 W for 2 h and autoradiographed at 7708C.
Immunohistochemistry
Immunohistochemistry was performed in 13 samples from 12 patients: nine pituitary tumours (including one intermediate lobe and one prolactinoma), three carcinoids (two ACTH secretors and a non-secretory tumour), and also the normal pituitary from one of the carcinoid patients, using a protocol described elsewhere (Fredersdorf et al., 1996) . Two normal pituitaries and a normal tonsil were used as additional controls (Figure 1a) . The tonsil is a very useful control as it contains lymphoid tissue which has variable proliferative activity: in the paracortical areas the cells are predominantly quiescent, while the germinal centres are highly proliferative (Fredersdorf et al., 1997) . All of the other tumours had been ®xed in Bouin's uid which contains picric acid and may interfere with the immunostaining protocol.
The monoclonal antibody used has previously been described (Fredersdorf et al., 1997) . In brief, the coding region of the human p27/kip1 was ampli®ed, cut at the BamHI site, and cloned into pGEX-2T; clones were screened for a 53 kD GST-p27/kip1 fusion protein, which was puri®ed and used to immunise Balb/c mice. Two mice with the highest titre on immunoblotting were used to carry out hybridoma fusion, and 200 clones positive for p27/kip1 but not GST were further screened by immunoblotting: two clones, SX18F7 and SX53G8, were found to have the highest anity for the p27/kip1 protein, the latter being used for these studies.
Formalin-®xed paran wax-embedded tissue blocks were cut at 3 mm, air-dried at room temperature for 1 h, then placed in a 608C oven overnight. A standard avidin-biotin immunoperoxidase technique was used. Endogenous peroxide was blocked with 0.5% hydrogen peroxide in methanol. Antigen retrieval was performed using the pressure cooker method as described by Norton et al. (1994) . Sections were pressure-cooked for 4 min in citrate buer 0.01 M pH 6.0. After three washes in phosphate buered saline (PBS), the slides were incubated with the primary antibody (1 : 50) for 40 min. The slides were then washed in PBS and incubated in biotinylated anti-mouse for 30 min, followed by avidin-biotin peroxidase complex for 20 min (Vectastain Elite ABC peroxidase kit, PK6200, Vector Labs, UK). After three washes in PBS, the slides were developed with activated 3,3-diaminobenzidine-tetrahydrochloride solution for 10 min, counterstained using haematoxylin, and dehydrated in alcohol before mounting in DPX. Positive controls using normal human tonsil sections were used in each batch of staining, while for negative controls primary antibody was replaced with mouse IgG (Biogenix, UK). All sections were examined by bright ®eld microscopy, and the intensity of nuclear staining graded as strongly positive (+++), moderately positive (++), weakly positive (+), or negative (7), by an observer blinded to the diagnosis.
